Hyperinsulinism due to UCP2 deficiency

Hyperinsulinism due to UCP2 deficiency (also known as UCP2-related hyperinsulinism) is a rare genetic form of congenital hyperinsulinism caused by mutations in the UCP2 gene, which encodes uncoupling protein 2. UCP2 normally functions in the mitochondria to regulate insulin secretion by pancreatic beta cells. When UCP2 is deficient or dysfunctional, beta cells become overly sensitive to glucose stimulation, leading to excessive and inappropriate insulin release (hyperinsulinism). This results in recurrent episodes of hypoglycemia (low blood sugar), which can be particularly dangerous in neonates and infants whose developing brains are highly vulnerable to glucose deprivation. The condition primarily affects the endocrine system, specifically the insulin-secreting beta cells of the pancreas. Key clinical features include recurrent hypoglycemia, which may present with symptoms such as seizures, lethargy, poor feeding, irritability, and in severe cases, loss of consciousness. If left untreated, persistent hypoglycemia can lead to permanent neurological damage. The severity of the condition can vary among affected individuals. Treatment typically involves medical management aimed at maintaining normal blood glucose levels. Diazoxide, which suppresses insulin secretion, is often used as a first-line therapy and patients with UCP2 deficiency generally respond well to this medication. Frequent feeding and glucose monitoring are also important components of management. In some cases, the hyperinsulinism may improve with age. The condition is considered rare, and long-term outcomes depend on the promptness of diagnosis and effectiveness of hypoglycemia prevention.

Common questions about Hyperinsulinism due to UCP2 deficiency